Pavel Reiterer

641 total citations
6 papers, 305 citations indexed

About

Pavel Reiterer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Pavel Reiterer has authored 6 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 1 paper in Cancer Research. Recurrent topics in Pavel Reiterer's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Pavel Reiterer is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Pavel Reiterer collaborates with scholars based in Australia, South Africa and Spain. Pavel Reiterer's co-authors include Luis Paz‐Ares, U. Gatzemeier, Aleksandra Szczęsna, Joachim von Pawel, Helen J. Ross, Mary O’Brien, E. Kaukel, Gary Middleton, David Readett and B. Bandstra and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Lung Cancer.

In The Last Decade

Pavel Reiterer

6 papers receiving 295 citations

Peers

Countries citing papers authored by Pavel Reiterer

Since Specialization

Citations

This map shows the geographic impact of Pavel Reiterer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pavel Reiterer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pavel Reiterer more than expected).

Fields of papers citing papers by Pavel Reiterer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pavel Reiterer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pavel Reiterer. The network helps show where Pavel Reiterer may publish in the future.

Co-authorship network of co-authors of Pavel Reiterer

This figure shows the co-authorship network connecting the top 25 collaborators of Pavel Reiterer. A scholar is included among the top collaborators of Pavel Reiterer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pavel Reiterer. Pavel Reiterer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

#	Work	Indexed citations
1	Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer 2011 ·Journal of Clinical Oncology ·Vera Hirsh, Luis Paz‐Ares, Michael Boyer, Rafael Rosell, Gary Middleton, Wilfried Eberhardt, Aleksandra Szczęsna, Pavel Reiterer, Mansoor N. Saleh, Óscar Arrieta, Emilio Bajetta, R. Timothy Webb, (unknown), Rebecca Benner, Camilla Fowst, Sandra J. Meech, David Readett, Joan H. Schiller	116
2	Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer 2008 ·British Journal of Cancer ·Luis Paz‐Ares, Helen J. Ross, Mary O’Brien, A. Riviére, U. Gatzemeier, Joachim von Pawel, E. Kaukel, L Freitag, W. Digel, Helge Bischoff, Rosario García‐Campelo, Nicholas Iannotti, Pavel Reiterer, Isabel Bover, J Prendiville, Amy J. Eisenfeld, F. B. Oldham, B. Bandstra, Jack W. Singer, Philip Bonomi	125
3	Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer 2005 ·Lung Cancer ·E.H. Tan, Aleksandra Szczęsna, Maciej Krzakowski, H.-N. Macha, U. Gatzemeier, K. Mattson, Martin Wernli, Pavel Reiterer, Rina Hui, Joachim von Pawel, Oscar Bertetto, Jean-Christophe Pouget, (unknown), Y Parlier, Raymond P. Abratt	44
4	O-099 XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): The STELLAR 2 phase III study 2005 ·Lung Cancer ·P. Bonomi, Luis Paz‐Ares, Corey J. Langer, Mary O’Brien, R. Gervais, U. Gatzemeier, Pavel Reiterer, С. В. Орлов, Helen J. Ross, Jean‐Marie Vandenbulcke	8
5	Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis 2004 ·Journal of Clinical Oncology ·Raymond P. Abratt, Aleksandra Szczęsna, K. Mattson, Martin Wernli, Pavel Reiterer, Rina Hui, (unknown), Oscar Bertetto, Martin Reck, Ee Hong Tan	6
6	Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Czech study. 1995 ·PubMed ·Zdeněk Adam, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Petr Průša, Pavel Reiterer, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact